Dapagliflozin Safe, Protective in Advanced Kidney Disease Dapagliflozin Safe, Protective in Advanced Kidney Disease
' For clinicians, this is now the absolute reassurance that we do not have to stop an SGLT2 inhibitor'in patients with advanced kidney disease, said Dr Chantal Mathieu, about the DAPA-CKD trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD
WEDNESDAY, July 21, 2021 -- For patients with stage 4 chronic kidney disease (CKD), a similar pattern of reduced kidney, cardiovascular, and mortality risks is seen with dapagliflozin versus placebo, with no evidence of increased risks, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 21, 2021 Category: Pharmaceuticals Source Type: news

Dapagliflozin's Cost-effectiveness'Intermediate' for HFrEF Dapagliflozin's Cost-effectiveness'Intermediate' for HFrEF
New analysis shows that despite reducing CV death in heart failure with reduced ejection fraction, the current cost of dapagliflozin makes it only an'intermediate'value in terms of cost-effectiveness.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

AstraZeneca Pharma, Abbott Healthcare terminate distribution agreements for diabetes drug in India
AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern respectively, the filing said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 28, 2021 Category: Pharmaceuticals Source Type: news

Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit
The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close in the DARE-19 trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 18, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Dapagliflozin did not significantly reduce organ failure or death in high-risk patients hospitalized
(American College of Cardiology) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 16, 2021 Category: Infectious Diseases Source Type: news

Farxiga Approved to Reduce Risk for CKD Progression
MONDAY, May 3, 2021 -- Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday. The drug is the first to be approved to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease
Based on results of the DAPA-CKD trial, the FDA has granted approval for the diabetes drug in patients with CKD at risk for disease progression.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 30, 2021 Category: Cardiology Tags: Nephrology News Alert Source Type: news

Dapagliflozin, Advanced Chronic Kidney Disease, and Mortality Dapagliflozin, Advanced Chronic Kidney Disease, and Mortality
A report on the effects of the SGLT2 inhibitor dapagliflozin on morbidity and mortality in patients with chronic kidney disease suggests these drugs have potential beyond their original use in T2DM.European Heart Journal (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 28, 2021 Category: Intensive Care Tags: Nephrology Journal Article Source Type: news

New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy
The landmark DAPA-CKD trial showed that dapagliflozin slows CKD progression regardless of diabetes status. Now a prespecified analysis suggests it also works for CKD patients with an IgA etiology.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 20, 2021 Category: Transplant Surgery Tags: Nephrology News Source Type: news

Dapagliflozin Quickly Reduces Heart Failure Events Dapagliflozin Quickly Reduces Heart Failure Events
A significant reduction of the incidence of cardiovascular death or worsening heart failure with dapagliflozin became apparent in DAPA-HF within 28 days after patients started treatment.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 23, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease
The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 6, 2021 Category: Pharmaceuticals Source Type: news

Drug Combo Offers Long-Term Glycemic Control in T2DM
FRIDAY, Nov. 6, 2020 -- For patients with type 2 diabetes and inadequate glycemic control, exenatide once weekly (QW) plus dapagliflozin shows clinically relevant efficacy and is well tolerated over 104 weeks, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 6, 2020 Category: Pharmaceuticals Source Type: news

Dapagliflozin Halves Hyperkalemia in Some HF Patients Dapagliflozin Halves Hyperkalemia in Some HF Patients
Dapagliflozin decreases moderate to severe hyperkalemia in heart failure (HF) patients treated with a mineralocorticoid receptor antagonist (MRA), a prespecified analysis of DAPA-HF data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 29, 2020 Category: Consumer Health News Tags: Nephrology News Source Type: news

Dapagliflozin's CKD Performance Sends Heart Failure Messages Dapagliflozin's CKD Performance Sends Heart Failure Messages
The DAPA-CKD trial results have important messages for cardiologists, especially heart failure physicians.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 5, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys'DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys '
Nephrologists Jennie Lin and Leslie Gewin discuss the effects of dapagliflozin in patients with CKD. How do the DAPA-CKD findings fit with the CREDENCE data on SGLT2 inhibitors?Medscape Nephrology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 4, 2020 Category: Intensive Care Tags: Nephrology Commentary Source Type: news

SGLT2 inhibitors can slow progression of chronic kidney disease
(ERA-EDTA) The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2020 Category: International Medicine & Public Health Source Type: news

DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
DAPA-CKD showed that dapagliflozin helped patients with albuminuria and declining eGFR, whether or not they also had type 2 diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 30, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Empagliflozin's HFrEF Benefit Solidifies Class Effects Empagliflozin's HFrEF Benefit Solidifies Class Effects
The 25% cut in primary endpoints among patients with HFrEF receiving empagliflozin in EMPEROR-Reduced matched the benefit seen before from dapagliflozin in DAPA-HF.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Dapagliflozin as add-on to metformin may reduce T2DM burden in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news

AstraZeneca Diabetes Drug Shows Promise in Severe Kidney Condition AstraZeneca Diabetes Drug Shows Promise in Severe Kidney Condition
Dapagliflozin has shown promise in a late-stage trial to help to slow chronic kidney disease, putting it on track for possible expanded approvals ahead of rival drugs.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 29, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Fewer Outpatient HF Med Adjustments on Dapagliflozin: DAPA-HF Fewer Outpatient HF Med Adjustments on Dapagliflozin: DAPA-HF
Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 27, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR
Treatment of patients with type 2 diabetes with the SGLT2 inhibitor led to a significant drop in the occurrence of'fast decline'of renal function in DECLARE-TIMI 58, the drug's main cardiovascular outcome trial.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 25, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients
Dapagliflozin cut the relative incidence of new-onset type 2 diabetes by one third in patients with heart failure in the multicenter trial.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 16, 2020 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

FDA OKs Farxiga for Heart Failure With Reduced Ejection Fraction
WEDNESDAY, May 6, 2020 -- The U.S. Food and Drug Administration has granted approval for Farxiga (dapagliflozin) oral tablets to treat adults with heart failure with reduced ejection fraction, the agency announced Tuesday. Farxiga is the first... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 6, 2020 Category: General Medicine Source Type: news

FDA Approves Diabetes Drug for Type of Heart Failure
The FDA today approved a new use for the diabetes drug, dapagliflozin (Farxiga), to reduce the risk of a hospital stay or death in people who have a type of heart failure. (Source: WebMD Health)
Source: WebMD Health - May 6, 2020 Category: Consumer Health News Source Type: news

FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure
The widely anticipated approval makes dapagliflozin (Farxiga, AstraZeneca) the only drug in its class to be indicated for heart failure in the absence of diabetes.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 6, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Farxiga Approved in the US for the Treatment of Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
6 May 2020 -- AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2020 Category: Drugs & Pharmacology Source Type: news

New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19. (Source: WebMD Health)
Source: WebMD Health - May 1, 2020 Category: Consumer Health News Source Type: news

New Study of Diabetes Drug for COVID-19 Raises Eyebrows New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 30, 2020 Category: Infectious Diseases Tags: Diabetes & Endocrinology News Source Type: news

Glenmark Pharma gets tentative USFDA nod for generic anti-diabetes tablets
Glenmark Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic Dapagliflozin and Saxagliptin anti-diabetes tablets. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 28, 2020 Category: Pharmaceuticals Source Type: news

Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 25, 2020 Category: Pharmaceuticals Authors: Brian Kaberline Source Type: news

Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 25, 2020 Category: Biotechnology Authors: Brian Kaberline Source Type: news

AstraZeneca and Saint Luke ’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure. (Source: World Pharma News)
Source: World Pharma News - April 23, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early
AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 31, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Granted Priority Review for Adults With Heart Failure Dapagliflozin Granted Priority Review for Adults With Heart Failure
The application for the SGLT2 inhibitor is based on the results from the landmark phase 3 DAPA-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 8, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D). (Source: World Pharma News)
Source: World Pharma News - January 6, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AHA Names Top Heart Disease, Stroke Research Advances of 2019 AHA Names Top Heart Disease, Stroke Research Advances of 2019
A watch that detects atrial fibrillation, prescription fish oil for CV risk reduction, and the promise of dapagliflozin in HF are among the major advances for 2019, says the American Heart Association.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 2, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Dec 6, 2019 This Week in Cardiology Dec 6, 2019 This Week in Cardiology
Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week's podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Making Room for New Drugs for Heart Failure Making Room for New Drugs for Heart Failure
Drs Ileana Pi ñ a and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity
The SGLT2 inhibitor showed about the same effect on its clinical primary end point in the very elderly and across all degrees of symptom status at baseline in two new analyses.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 25, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

FDA OKs Diabetes Drug for Type 2 Heart Failure Risk
The FDA granted a new use for diabetes drug Farxiga (dapagliflozin): to reduce the risk of hospitalization for heart failure in adults who have type 2 diabetes and established heart disease or risk factors for it. (Source: WebMD Health)
Source: WebMD Health - October 22, 2019 Category: Consumer Health News Source Type: news

FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes
Dapagliflozin (Farxiga, AstraZeneca) has additionally been approved in the US for reducing hospitalization for heart failure (HF) in adults with type 2 diabetes and other cardiovascular risk factors.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 21, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Farxiga (dapagliflozin) to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes
21 October 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) and established... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 21, 2019 Category: Drugs & Pharmacology Source Type: news

What Do You Think of Dapagliflozin for Heart Failure? What Do You Think of Dapagliflozin for Heart Failure?
Recent trial results indicate that the diabetes drug provides substantial benefits for heart failure patients, even those without diabetes.Medscape Reader Polls (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 2, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Dapagliflozin Lowers Risk for Worsening Heart Failure
MONDAY, Sept. 23, 2019 -- For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 23, 2019 Category: Pharmaceuticals Source Type: news

EU Panel Votes to Expand Dulaglutide Indication Based on REWIND EU Panel Votes to Expand Dulaglutide Indication Based on REWIND
The panel also recommends approval of Qtrilmet, a fixed-dose combination of metformin hydrochloride/saxagliptin/dapagliflozin for treatment of type 2 diabetes.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Sep 20 2019 This Week in Cardiology Sep 20 2019 This Week in Cardiology
The polypill, dapagliflozin, TAVR, and video games are discussed by John Mandrola, MD, in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 20, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Diabetes drug also treats heart failure, researchers say
Dapagliflozin was found to cut death rates and hospital stays and improve patient's quality of life. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 19, 2019 Category: Consumer Health News Source Type: news